# National Authority of Medicines and Health Products, I.P.

CERTIFICATE NUMBER: FT055/MH/001/2018

# CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

#### Part 1

Issued following an inspection in accordance with:

Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Portugal confirms the following:

The manufacturer: *Eugia Pharma Specialities Limited* 

Site address: Survey No 550 551 And 552, Kolthur Village Shameerpet Mandal, Medchal Malkajgiri

District, Medchal, Hyderabad, 500101, India

OMS Organisation Id. / OMS Location Id.: ORG-100031553 / LOC-100049449

DUNS Number: 87-220-1704

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art. 111(4) of Directive 2001/83/EC.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2022-11-25, it is considered that it complies with:

• The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572 and Commission Delegated Regulation (EU) 2017/1569 <sup>3</sup>

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

Online EudraGMDP, Ref key: 157409 Issuance Date 2023-01-30 Signatory: Confidential Page 1 of 3

<sup>&</sup>lt;sup>1</sup>The certificate referred to in paragraph Art. 111(5) of Directive 2001/83/EC, shall also be required for imports coming from third countries into a Member State

<sup>&</sup>lt;sup>2</sup>Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

<sup>&</sup>lt;sup>3</sup>These requirements fulfil the GMP recommendations of WHO.

### Part 2

## **Human Medicinal Products**

1 MANUFACTURING OPERATIONS			
1.1	Sterile products		
	1.1.1	Aseptically prepared (processing operations for the following dosage forms)	
		1.1.1.1 Large volume liquids	
		Special Requirements	
		7 Other: cytotoxic(en)	
		1.1.1.2 Lyophilisates	
		Special Requirements	
		7 Other: cytotoxic(en)	
		1.1.1.4 Small volume liquids	
		Special Requirements	
		7 Other: hormones, cytotoxic(en)	
	1.1.2	Terminally Sterilised (processing operations for the following dosage forms)	
		1.1.2.3 Small volume liquids	
		Special Requirements	
		7 Other: cytotoxic(en)	
1.2	NI	4	
1.2	1.2.1	Non-stavila madveta (specializa engustions for the following degree forms)	
	1.2.1	Non-sterile products (processing operations for the following dosage forms)	
		1.2.1.1 Capsules, hard shell	
		Special Requirements 7 Other: cytotoxic(en)	
		1.2.1.2 Capsules, soft shell	
		Special Requirements	
		7 Other: hormones, cytotoxic(en)	
		1.2.1.13 Tablets	
		Special Requirements	
		7 Other: cytotoxic(en)	

1.5	ickaging		
	1.5.1 Primary Packaging		
	1.5.1.1 Capsules, hard shell Special Requirements 7 Other: cytotoxic(en)		
	1.5.1.2 Capsules, soft shell Special Requirements 7 Other: hormones, cytotoxic(en)		
	1.5.1.13 Tablets Special Requirements 7 Other: cytotoxic(en)		
	1.5.2 Secondary packaging		
1.6	Quality control testing		
	1.6.1 Microbiological: sterility		
	1.6.2 Microbiological: non-sterility		
	1.6.3 Chemical/Physical		

Clarifying remarks (for public users)

Oncology Block - 1.1.1.1 Lines 1 and 2; 1.1.1.2 Line 1; 1.1.1.4 Lines 1 and 2; 1.1.2.3 Lines 1 and 2. Hormone Block - 1.1.1.4 Vial and pre-filled syringe. - The complete address is Survey No 550 551 And 552, Kolthur Village Shamirpet Mandal, Medchal Malkajgiri District, Hyderabad, Telangana, 500101 – India. - Following the inspection of 21st to 25th November 2022, this GMP Certificate is valid until the end of 2023, until reception and assessment of CAPA plan.